Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

Open access
Crawford, James J., Johnson, Adam R., Misner, Dinah L., Belmont, Lisa D., Castanedo, Georgette, Choy, Regina, Coraggio, Melis, Dong, Liming, Eigenbrot, Charles, Erickson, Rebecca, Ghilardi, Nico, Hau, Jonathan, Katewa, Arna, Kohli, Pawan Bir, Lee, Wendy, Lubach, Joseph W., McKenzie, Brent S., Ortwine, Daniel F., Schutt, Leah, Tay, Suzanne, Wei, BinQing, Reif, Karin, Liu, Lichuan, Wong, Harvey, Young, Wendy B.·2018·Journal of Medicinal Chemistry

Abstract

Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here we disclose the discovery and preclinical characterization of a potent, selective, and noncovalent Btk inhibitor currently in clinical development. GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis. It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria. On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunological indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b01712

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 257

Metadata

Authors
Crawford, J. J., Johnson, A. R., Misner, D. L., Belmont, L. D., Castanedo, G., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C., Erickson, R., Ghilardi, N., Hau, J., Katewa, A., Kohli, P. B., Lee, W., Lubach, J. W., McKenzie, B. S., Ortwine, D. F., Schutt, L., Tay, S., Wei, B., Reif, K., Liu, L., Wong, H., & Young, W. B.
Venue
Journal of Medicinal Chemistry
Published
2018-02-19
Volume
61
Issue
6
Pages
2227-2245
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2788356134
Cited by
257
References
54
FWCI
21.10
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b01712
The paper
Crawford, J. J., Johnson, A. R., Misner, D. L., Belmont, L. D., Castanedo, G., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C., Erickson, R., Ghilardi, N., Hau, J., Katewa, A., Kohli, P. B., Lee, W., Lubach, J. W., McKenzie, B. S., Ortwine, D. F., Schutt, L., . . . Young, W. B. (2018). Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b01712

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.